-

Bayer Earns Top Score on 2022 Disability Equality Index 

Bayer U.S. Again Recognized as a Best Place to Work for Disability Inclusion

WHIPPANY, N.J.--(BUSINESS WIRE)--For the fourth consecutive year, Bayer U.S. has been awarded and recognized by The Disability Equality Index (DEI) as a Best Place to Work for Disability Inclusion. This is the second year that Bayer has received a top score of 100% in the DEI, which is the most comprehensive disability inclusion tool designed and embraced by both business leaders and disability advocates across the country. Since 2019, Bayer’s DEI score has improved year-over-year, recognizing the company’s continued growth.

“Bayer is a workplace that embraces employees with disabilities. Earning a top score and being recognized as a best place to work yet again showcases the dedication and hard work we’ve put into bettering the lives of our employees and communities we serve,” said Beth Roden, Senior Vice President and Head of Communications, Bayer U.S., Head of Communications, Consumer Health, North America, and the U.S. Co-Executive Sponsor for ENABLE, Bayer’s Business Resource Group dedicated to supporting employee wellness and support to families with disabilities. “As one of the country’s leading life-sciences companies, creating an environment built upon fairness and justice is crucial. Treating employees with unique needs and circumstances fairly means being inclusive, diverse, accessible and equitable to all.”

As part of Bayer’s inclusive vision, Health for All, Hunger for None, the company embraces and values diversity in ideas, perspectives as well as cultures. The U.S. Executive Inclusion and Diversity Council and Business Resource Groups (BRGs) are a vital part of the company’s Inclusion and Diversity strategy. ENABLE, one of Bayer’s Resource Groups, supports employees who have disabilities, or family members with disabilities, leveraging a network to help them manage situations at home, while maintaining focus at work. They partner with leaders from across the organization to build awareness and improve access to facilities, opportunities, and resources.

“Employees with disabilities are an integral part of Bayer’s workforce, and ensuring all feel a sense of belonging is key factor in being one of the country’s best places to work,” said Shakti Harris, Head of Bayer’s Inclusion & Diversity in the U.S “Not only is it the right thing to do, but it’s this uniqueness and culture that allow Bayer to innovate, solve for the world’s biggest challenges and pursue our inclusive vision of Health for All, Hunger for None.”

The DEI was launched in 2015 by Disability:IN and The American Association of People with Disabilities (AAPD) and is acknowledged today as the most robust disability inclusion assessment tool in business. It was created by the DEI Advisory Committee, a diverse group of business leaders, policy experts and disability advocates. Now in its eighth year, the DEI exists to help businesses make a positive impact on the unemployment/underemployment of people with disabilities.

“Disability inclusion is a rapidly expanding aspect of corporate culture, and it’s gratifying to partner with 415 companies on the 2022 Disability Equality Index,” said Jill Houghton, President and CEO of Disability: IN. “These top-scoring companies not only excel in disability inclusion, but many are also adopting emerging trends and pioneering measures that can move the disability agenda from accommodation to inclusion and ultimately, genuine belonging.

In 2022, 415 corporations, including 69 Fortune 100, 188 Fortune 500, and 227 Fortune 1000 utilized the DEI to benchmark their disability inclusion efforts. Out of 415 participants, 240 companies received a score of 100.

For more information on the 2022 Disability Equality Index, visit https://disabilityin.org.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability, and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses before special items amounted to 5.3 billion euros. For more information, go to www.bayer.com.

About the Disability Equality Index®

The Disability Equality Index (DEI) is a comprehensive benchmarking tool that helps companies build a roadmap of measurable, tangible actions that they can take to achieve disability inclusion and equality. Each company receives a score, on a scale of zero (0) to 100, with those earning 80 and above recognized as a “Best Place to Work for Disability Inclusion.” The DEI is a joint initiative of the American Association of People with Disabilities (AAPD), the nation’s largest disability rights organization, and Disability: IN, the global business disability inclusion network, to collectively advance the inclusion of people with disabilities. The organizations are complementary and bring unique strengths that make the project relevant and credible to corporations and the disability community. The tool was developed by the DEI Advisory Committee, a diverse group of business leaders, policy experts, and disability advocates. Learn more at: www.DisabilityEqualityIndex.org.

About the American Association of People with Disabilities (AAPD)

AAPD is a convener, connector, and catalyst for change, increasing the political and economic power for people with disabilities. As a national cross-disability rights organization AAPD advocates for full civil rights for the 50+ million Americans with disabilities. Learn more at: www.aapd.com.

About Disability:IN®

Disability:IN is a global organization driving disability inclusion and equality in business. More than 270 corporations trust Disability:IN to activate and achieve disability inclusion across their enterprise and in the broader corporate mainstream. Through the world’s most comprehensive disability inclusion benchmarking; best-in-class conferences and programs; and expert counsel and engagement, Disability:IN works with leading businesses to create long-term business and societal impact. Join us at disabilityin.org/AreYouIN #AreYouIN.

Social Media Channels

- Facebook: BayerUnitedStates
- Twitter: BayerUS
- Instagram: BayerUS
- YouTube: BayerUS

Bayer® and the Bayer Cross® are registered trademarks of Bayer.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Contacts

DEI:
Name: Becky Curran Kekula
Email: Becky@DisabilityIN.org
Number: (781) 424-4203

Bayer Media
Name: Nicole Hayes
Email: Nicole.Hayes@Bayer.com
Phone: (201) 421-5268

Bayer


Release Versions

Contacts

DEI:
Name: Becky Curran Kekula
Email: Becky@DisabilityIN.org
Number: (781) 424-4203

Bayer Media
Name: Nicole Hayes
Email: Nicole.Hayes@Bayer.com
Phone: (201) 421-5268

More News From Bayer

Robigo and Leaps by Bayer Announce Series A Financing to Advance Engineered Biologicals That Protect Yields and Reduce Costs

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Robigo, a biotechnology company engineering no-compromise biological solutions for crop protection, today announced a Series A funding led by Leaps by Bayer with participation from Illumina Ventures, SVG Thrive, Congruent Ventures, and Endeavor8. The round will accelerate the commercial launch of engineered microbial biopesticides combatting fungal diseases in soybeans and specialty crops in the United States, making these biologicals economically viable witho...

Bayer’s KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA® (finerenone) to reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline and end-stage kidney disease in adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D), following the agency’s Priority Review of the supplemental New Drug Application (...

Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road

WHIPPANY, N.J.--(BUSINESS WIRE)--Amid growing concerns over misinformation around health and science, Bayer launched a nationwide tour of its Science Delivers mobile interactive experience. The mobile display hits the road at a critical moment: a Harris Poll survey of 2,023 US adults, commissioned by Bayer – Science Under Siege: The Battle Between Viral Misinformation and Shared Belief in the Value of Science (March 2026) – found that 82% worry about their own and their families' wellbeing due...
Back to Newsroom